1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Blue Jet Healthcare Limited

Blue Jet Healthcare Limited

475.30
INR
-12.90
(-2.64%)
15.80EPS
33.04P/E
90.56BMarket Cap
Nov 05Next Earn
Blue Jet Healthcare Limited
BSE:BLUEJET
(Bombay Stock Exchange)

Recent

price

475.30

P/E

ratio

33.04

div

yld

- -

ROIC.AI

2021
2022
2023
2024
2025
2026
TTM
INR
28.58
39.11
41.54
40.95
59.15
54.45
62.01
Revenue per Share
7.98
10.47
9.23
9.44
17.59
14.29
15.8
Basic EPS, GAAP
4.62
7.12
4.74
3.86
-1.97
6.61
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
1
1.2
- -
Dividend per Share
19.59
30.07
39.29
48.73
65.32
78.4
- -
Book Value per Share
19.59
30.07
39.28
48.71
65.29
78.27
- -
Tangible Book Value per Share
173
173
173
173
173
173
173
Basic Weighted Avg Shares
4,957
6,785
7,205
7,103
10,261
9,444
10,750
Sales/Revenue/Turnover
37.6
33.53
26.93
28.51
35.08
28.6
29.06
Operating Margin (%)
197
218
251
281
178
240
248
Depreciation Expense
1,384
1,816
1,600
1,638
3,052
2,478
2,739
Net Income, GAAP
26.47
25.34
26.12
25.6
24.85
25.47
25.91
Effective Tax Rate (%)
27.92
26.76
22.21
23.05
29.74
26.24
25.48
Profit Margin (%)
2,269
3,738
4,912
4,997
7,500
7,296
- -
Working Capital
287
133
15
4
165
376
- -
LT Debt
3,398
5,215
6,815
8,452
11,331
13,599
- -
Total Equity
- -
31.84
20.64
15.35
21.56
13.48
- -
Return on Invested Capital (%)
- -
39.57
26.32
21.4
30.53
19.76
- -
Return on Capital (%)
- -
42.16
26.6
21.45
30.85
19.88
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
46
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
376
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
173
173
173
Market Capitalization
91,928
56,767
90,558

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
9,570
- -
Cash, Cash Equivalents & STI
- -
3,234
- -
Accounts Receivable, Net
- -
3,390
- -
Inventories
- -
1,874
- -
Total Current Liabilities
- -
2,275
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
46
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
32.45%
20.02%
Free Cash Flow
- -
-117%
-436.16%
Net Income, GAAP
- -
17.84%
-18.8%
Sales/Revenue/Turnover
- -
15.63%
-7.96%
Total Cash Common Dividend
- -
- -
20%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1,629
2,083
3,184
3,404
10,261
2026
3,548
- -
1,924
2,347
9,444
2027
2,931
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
2.18
3.36
5.71
6.35
17.59
2026
5.26
- -
2.32
3.71
14.29
2027
4.51
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
1
2026
- -
- -
- -
- -
1.2
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Blue Jet Healthcare Limited is an India-based pharmaceutical company specializing in the manufacturing and sale of contrast media intermediates, high-intensity sweeteners, pharmaceutical intermediates, and active pharmaceutical ingredients (APIs). Founded in 1968 and headquartered in Mumbai, the company serves innovator pharmaceutical firms, multinational generic pharmaceutical companies, research laboratories, and FMCG sectors globally. Its main product categories include contrast media intermediates used to enhance diagnostic imaging in X-rays, CT scans, and MRIs; pharmaceutical intermediates and APIs targeting niche and complex molecules for anti-infectives, CNS drugs, cardiovascular and gastrointestinal treatments; and high-intensity sweeteners, primarily saccharin and related salts, for healthcare and food industries. Blue Jet Healthcare also provides contract development and manufacturing services (CDMO) with specialized chemistry capabilities. Recent major developments include a strategic greenfield expansion project in Andhra Pradesh with over ₹1,000 crore investment to augment global CDMO capacities and deepen engagement with international customers, reflecting a significant push to scale operations and technological capabilities. The company, which evolved from Jet Chemicals Pvt Ltd, has changed its corporate status and name multiple times since incorporation, most recently becoming Blue Jet Healthcare Limited in 2022. It operates internationally with regulatory approvals including US FDA and ISO certifications, positioning itself as a science-led partner in pharmaceutical ingredient development and manufacturing across several countries including India, Norway, France, the United States, Italy, and Sweden. The expansion and diversification into CDMO services mark a strategic shift for Blue Jet Healthcare towards building a robust global manufacturing footprint in advanced pharmaceutical intermediates and APIs.